secwatch.observer — SEC 8-K summary
======================================

Issuer:     Embecta Corp. (EMBC)
CIK:        0001872789
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001872789-22-000019
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Embecta reports Q4 FY2022 net loss $17.2M; FY2023 guidance revenue $1,050-$1,073M
--------------------------------------------------------------------------------

- Q4 revenue $274.6M, down 8.7% reported; net loss $17.2M vs income $97.1M prior year, includes $58.9M impairment.
- FY2022 revenue $1,129.5M, down 3.1%; net income $223.6M vs $414.8M; adjusted EBITDA margin 40.7% vs 48.5%.
- Quarterly dividend $0.15/share declared, payable Jan 11, 2023 to holders of record Dec 30, 2022.
- Preliminary FY2023 guidance: revenue $1,050-$1,073M (down 5-7% reported); adj. diluted EPS $1.75-$2.00.
- Entered co-promotion agreement with Intuity Medical for POGO Automatic blood glucose monitor in U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1872789/000187278922000019/0001872789-22-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1872789/000187278922000019/embc-20221220.htm
  HTML page:      https://secwatch.observer/filing/0001872789-22-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer